Ready to start planning your care? Call us at 800-525-2225 to make an appointment.
Tow Center for Developmental Oncology
About the Tow Center for Developmental Oncology
The Tow Center for Developmental Oncology unites scientists across MSK to develop fundamental insights into the molecular mechanisms of cancers in children and young adults, and to devise new approaches for definitive therapy and control.
The Tow Center for Developmental Oncology brings together investigators from across all of MSK. This includes basic scientists from the Sloan Kettering Institute, experts from MSK Kids (MSK’s pediatric program), and physician-scientists from Memorial Hospital and the Human Oncology & Pathogenesis Program.
Faculty Recruitment for the Tow Center for Developmental Oncology
The Tow Center for Developmental Oncology is recruiting scientists to join our world-renowned faculty conducting research focused on the biology, physiology, and molecular mechanisms of cancers in children and young adults. MSK’s ultimate goal is to make fundamental discoveries to develop definitive treatments for patients.
The US Food and Drug Administration (FDA) has approved the drug naxitamab (Danyelza) for the treatment of patients with high-risk neuroblastoma. The drug, also known as humanized 3F8, was developed by researchers at MSK Kids, the pediatric cancer program at Memorial Sloan Kettering.
Essential philanthropic support from The Tow Foundation and other generous donors allows the Tow Center for Developmental Oncology to advance research and care for kids with cancer worldwide.
The Robert Steel Symposium in Developmental Oncology aims to bring outstanding scientists across the country to discuss the latest discoveries into the molecular mechanisms of cancers in children and young adults, and the development of new approaches for their definitive therapy and control.
